Exjade Side Effects
Generic name: deferasirox
Note: This document contains side effect information about deferasirox. Some of the dosage forms listed on this page may not apply to the brand name Exjade.
Some side effects of Exjade may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to deferasirox: oral tablet for suspension
Along with its needed effects, deferasirox (the active ingredient contained in Exjade) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking deferasirox:More common
- Abdominal pain
- earache or pain in the ear
- voice changes
- blurred vision
- change in hearing
- change in vision
- pain or discomfort in the eye
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- dark-colored urine
- decrease in urine amount
- general feeling of tiredness or weakness
- hives or welts
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- light-colored stools
- lower back or side pain
- pale skin
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness, soreness or itching of the skin
- skin rash
- sores, welting, or blisters
- stomach pain, continuing
- unusual bleeding or bruising
- vomiting of blood or material that looks like coffee grounds
- yellow eyes or skin
For Healthcare Professionals
Applies to deferasirox: oral tablet dispersible
General side effects including pyrexia (18.9%), headache (15.9%), abdominal pain (13.9%), influenza (10.8%), upper abdominal pain (7.8%), and fatigue (6.1%) have been reported.
Respiratory side effects including cough (13.9%), nasopharyngitis (13.2%), pharyngolaryngeal pain (10.5%), respiratory tract infection (9.5%), bronchitis (9.1%), pharyngitis (7.8%), and rhinitis (6.1%) have been reported.
Gastrointestinal side effects including diarrhea (11.8%), nausea (10.5%), vomiting (10.1%), and upper gastrointestinal ulceration and hemorrhage have been reported.
Nonprogressive increases in serum creatinine have been noted in 38% of deferasirox-treated patients and appear to be dose related. These increases were within the normal range in 94% of patients. Deferasirox dosages had been adjusted once serum creatinine elevations were detected during the study. Dose reduction, interruption, or discontinuation should be considered for elevations in serum creatinine. If there is a progressive increase in serum creatinine beyond the age-appropriate upper limit of normal, deferasirox (the active ingredient contained in Exjade) should be interrupted. Once the creatinine has returned to within the normal range, therapy with deferasirox may be reinitiated at a lower dose followed by gradual dose escalation, if the clinical benefit is expected to outweigh potential risks.
Intermittent proteinuria (urine protein/creatinine ratio greater than 0.6 mg/mg) has been reported in 18.6% of deferasirox treated patients. Monthly monitoring is recommended.
Renal side effects including increased creatinine, intermittent proteinuria, and renal tubulopathy have been reported. There have also been postmarketing reports of acute renal failure and tubulointerstitial nephritis.
Dermatologic side effects including rash (8.4%), urticaria (3.7%), and postmarketing reports of leukocytoclastic vasculitis, urticaria, and alopecia have been reported.
Musculoskeletal side effects including arthralgia (7.4%) and back pain (5.7%) have been reported.
Immunologic side effects including acute tonsillitis (6.4%) have been reported.
Other side effects including ear infection (5.4%), high-frequency hearing loss, and decreased hearing have been reported.
Hepatic side effects have included two patients with drug-induced hepatitis and two patients with increased serum transaminases who discontinued use of deferasirox (the active ingredient contained in Exjade) because of these hepatic abnormalities. There have been postmarketing reports of hepatic failure, some with a fatal outcome, in patients treated with deferasirox. Most of these events occurred in patients greater than 55 years of age. Seventeen of the patients in the clinical trials developed elevations in SGPT/ALT levels greater than five times the upper limit of normal at two consecutive visits.
Most reports of hepatic failure involved patients with significant comorbidities, including liver cirrhosis and multiorgan failure.
Increases in transaminases were not dose related.
Although most of these patients had preexisting hematologic disorders that are frequently associated with bone marrow failure, a contributory role for deferasirox (the active ingredient contained in Exjade) could not be excluded.
Hematologic side effects have included cytopenias such as agranulocytosis, neutropenia, thrombocytopenia and postmarketing reports of worsening anemia.
If reactions are severe, deferasirox (the active ingredient contained in Exjade) should be discontinued and appropriate medical intervention instituted.
Hypersensitivity side effects including postmarketing reports of anaphylaxis and angioedema have been reported.
Ocular side effects including lens opacities, cataracts, elevations in intraocular pressure, and retinal disorders have been reported with deferasirox (the active ingredient contained in Exjade) therapy in less than 1% of patients in clinical trials.
Ophthalmic testing (including slit lamp examinations and dilated fundoscopy) are recommended before the start of deferasirox treatment and thereafter every 12 months.
More Exjade resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.